EUVIMEDEUVIMED entdecken
Klinische StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Brief Report: A Pilot Study Evaluating the Feasibility, Safety, and Compliance With a Fasting-Mimicking Diet in Patients With Metastatic Non–Small Cell Lung Cancer

Fatima Ghaddar, Shahid Ahmed, Beth Kirsch, Laura Jennewein, Margaret M Uhrich, Sandra K Althouse, Valter Longo, Shadia Jalal

Clinical Lung Cancer · 2026

DOI: 10.1016/j.cllc.2026.03.017 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Clinical Lung Cancer, 2026. Verfasst von Fatima Ghaddar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN. Electronic address: fag03@mail.aub.edu. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Fasting, Lung Neoplasms, Patient Compliance. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The fasting-mimicking diet (FMD) is a plant-based, calorie-restricted, low-carbohydrate, low-protein, 4- or 5-day diet that reproduces short-term fasting physiology and promotes synergy with cancer therapies. Despite established safety and feasibility, FMD data in advanced lung cancer remain lacking. MATERIALS AND METHODS: This open-label, single-arm, single-center pilot study recruited metastatic non-small cell lung cancer (NSCLC) adult patients (Body mass index >18, Eastern Cooperative Oncology Group performance status [PS] 0-2) who were clinically stable on first-line therapy for ≥2 months. Patients received one 4-day FMD. Primary outcomes were feasibility (proportion completing FMD), safety (proportion completing FMD without grade 3-4 adverse events), and compliance with FMD caloric requirements. Weight and biologic measures-complete blood counts and metabolic panels-were obtained at baseline and 21 or 28 days post-FMD. Weight was also measured during FMD. The secondary outcome was self-reported willingness to repeat FMD. RESULTS: Ten participants initiated FMD. Median age was 57.2 years (40.5, 76.2), median baseline Body mass index 28.1 (22.6, 37.5), and baseline Eastern Cooperative Oncology Group PS 0-1. Most patients were female (70%), had adenocarcinoma (90%), and received oral targeted therapy (80%). Fifty percent were White/Caucasian, 30% Black/African American, and 20% Asian. Ninety percent completed FMD. No grade 3 to 4 adverse events occurred. Most common side effects were grades 1 to 2-nausea (30%), abdominal pain (20%), fatigue (20%), headache (20%). Weight loss remained < 10% from baseline. Biologic markers were normal. Compliance rate was 70% (95% CI, 34.8-93.3). Eighty percent of patients expressed willingness to repeat FMD. CONCLUSION: A single FMD cycle is safe and feasible in relatively young, advanced NSCLC patients on oral targeted therapy. CLINICAL TRIAL INFORMATION: ClinicalTrials.gov Identifier: NCT03700437.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungFastingLung NeoplasmsPatient ComplianceAdultAgedFemaleHumansMaleMiddle AgedDiet, Plant-BasedFeasibility StudiesPilot Projects

Stichwörter der Autor:innen

Advanced lung cancerDietary interventionFastingFeasibility studyPilot clinical trial

Autor:innen und Institutionen

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN. Electronic address: fag03@mail.aub.edu.
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN. Electronic address: shahid.sattar.ahmed@emory.edu.
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN. Electronic address: bkirsch@iuhealth.org.
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN. Electronic address: laura.e.jennewein@gmail.com.
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN. Electronic address: muhrich@iu.edu.
  • Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN. Electronic address: salthous@iu.edu.

Zitieren

APA

Ghaddar, F., Ahmed, S., Kirsch, B., Jennewein, L., Uhrich, M. M., Althouse, S. K., Longo, V., & Jalal, S. (2026). Brief Report: A Pilot Study Evaluating the Feasibility, Safety, and Compliance With a Fasting-Mimicking Diet in Patients With Metastatic Non–Small Cell Lung Cancer. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2026.03.017

Vancouver

Ghaddar F, Ahmed S, Kirsch B, Jennewein L, Uhrich MM, Althouse SK, et al. Brief Report: A Pilot Study Evaluating the Feasibility, Safety, and Compliance With a Fasting-Mimicking Diet in Patients With Metastatic Non–Small Cell Lung Cancer. Clinical Lung Cancer. 2026. doi:10.1016/j.cllc.2026.03.017

BibTeX
@article{Ghaddar2026,
  author = {Ghaddar, Fatima and Ahmed, Shahid and Kirsch, Beth and Jennewein, Laura and Uhrich, Margaret M and Althouse, Sandra K and Longo, Valter and Jalal, Shadia},
  title = {Brief Report: A Pilot Study Evaluating the Feasibility, Safety, and Compliance With a Fasting-Mimicking Diet in Patients With Metastatic Non–Small Cell Lung Cancer},
  journal = {Clinical Lung Cancer},
  year = {2026},
  doi = {10.1016/j.cllc.2026.03.017}
}
Kostenlos starten →